Allergan builds obesity treatment portfolio
This article was originally published in The Gray Sheet
Executive Summary
Allergan will pursue FDA approval of EndoArt's EasyBand remote-controlled gastric banding system for treatment of morbid obesity after acquiring the Swiss company for $97 million, the firm announces Feb. 22. The "next-generation" implant, intended for placement around the upper stomach, allows telemetric adjustment via an external controller to fit each patient's individual weight loss needs, the company says. Approved in Europe in mid-2006, EasyBand complements Allergan's Lap-Band adjustable gastric banding system. Allergan gained Lap-Band - currently the only adjustable implant for individualized weight loss approved in the United States - in its $3.2 billion purchase of Inamed last year (1"The Gray Sheet" April 3, 2006, p. 6). Allergan also offers its nonsurgical BIB BioEnterics intragastric balloon for obesity treatment outside the United States...
You may also be interested in...
Allergan Details Revenue Expectations From Newly Acquired Inamed
Allergan expects its recently completed acquisition of Inamed to add $355 mil. to $395 mil. in sales revenue this year
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.